白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2010年
2期
82-83,87
,共3页
淋巴瘤,非霍奇金%抗肿瘤联合化疗方案%随机对照试验
淋巴瘤,非霍奇金%抗腫瘤聯閤化療方案%隨機對照試驗
림파류,비곽기금%항종류연합화료방안%수궤대조시험
Lymphoma,non-Hodgkin%Antineoplastic combined chemotherapy protocols%Bandomized controlled trials
目的 观察沙利度胺在侵袭性非霍奇金淋巴瘤(NHL)中的治疗作用及不良反应.方法 52例侵袭性恶性淋巴瘤患者,随机分为两组,每组26例.CHOP组:环磷酰胺600 mg/m~2静脉注射第1天;表柔比星50 mg/m~2,静脉注射第1天;长春新碱1.4 mg/m~2,静脉注射第1天,泼尼松50 mg/m~2,口服,第1天至第7天.沙利度胺组:化疗方案同CHOP组,加用沙利度胺,200 mg第1天至第14天,口服,第2个疗程剂量增加为400mg,第1天至第14天.结果 CHOP组CR 7例(26.9%),PR 12例(46.2%),CR+PR 19例,总有效率为73.1%;沙利度胺组CR 9例(34.6%),PR 14例(53.8%),CR+PR 23例,总有效率为88.4%;两组比较差异无统计学意义(P=0.25).沙利度胺组1年生存率(OS)92.6%,2年OS为83.5%,CHOP组分别为90.8%、68.8%,两组1年OS差异无统计学意义,2年OS差异有统计学意义(P＜0.05).沙利度胺组外周神经毒性、便秘、疲乏等不良反应发生率高于CHOP组,两组比较差异有统计学意义(P＜0.05).结论 沙利度胺联合CHOP方案治疗侵袭性NHL,不良反应可以耐受,且在缓解率及生存期方面均优于单纯化疗组.
目的 觀察沙利度胺在侵襲性非霍奇金淋巴瘤(NHL)中的治療作用及不良反應.方法 52例侵襲性噁性淋巴瘤患者,隨機分為兩組,每組26例.CHOP組:環燐酰胺600 mg/m~2靜脈註射第1天;錶柔比星50 mg/m~2,靜脈註射第1天;長春新堿1.4 mg/m~2,靜脈註射第1天,潑尼鬆50 mg/m~2,口服,第1天至第7天.沙利度胺組:化療方案同CHOP組,加用沙利度胺,200 mg第1天至第14天,口服,第2箇療程劑量增加為400mg,第1天至第14天.結果 CHOP組CR 7例(26.9%),PR 12例(46.2%),CR+PR 19例,總有效率為73.1%;沙利度胺組CR 9例(34.6%),PR 14例(53.8%),CR+PR 23例,總有效率為88.4%;兩組比較差異無統計學意義(P=0.25).沙利度胺組1年生存率(OS)92.6%,2年OS為83.5%,CHOP組分彆為90.8%、68.8%,兩組1年OS差異無統計學意義,2年OS差異有統計學意義(P＜0.05).沙利度胺組外週神經毒性、便祕、疲乏等不良反應髮生率高于CHOP組,兩組比較差異有統計學意義(P＜0.05).結論 沙利度胺聯閤CHOP方案治療侵襲性NHL,不良反應可以耐受,且在緩解率及生存期方麵均優于單純化療組.
목적 관찰사리도알재침습성비곽기금림파류(NHL)중적치료작용급불량반응.방법 52례침습성악성림파류환자,수궤분위량조,매조26례.CHOP조:배린선알600 mg/m~2정맥주사제1천;표유비성50 mg/m~2,정맥주사제1천;장춘신감1.4 mg/m~2,정맥주사제1천,발니송50 mg/m~2,구복,제1천지제7천.사리도알조:화료방안동CHOP조,가용사리도알,200 mg제1천지제14천,구복,제2개료정제량증가위400mg,제1천지제14천.결과 CHOP조CR 7례(26.9%),PR 12례(46.2%),CR+PR 19례,총유효솔위73.1%;사리도알조CR 9례(34.6%),PR 14례(53.8%),CR+PR 23례,총유효솔위88.4%;량조비교차이무통계학의의(P=0.25).사리도알조1년생존솔(OS)92.6%,2년OS위83.5%,CHOP조분별위90.8%、68.8%,량조1년OS차이무통계학의의,2년OS차이유통계학의의(P＜0.05).사리도알조외주신경독성、편비、피핍등불량반응발생솔고우CHOP조,량조비교차이유통계학의의(P＜0.05).결론 사리도알연합CHOP방안치료침습성NHL,불량반응가이내수,차재완해솔급생존기방면균우우단순화료조.
Objective To determine the curative effect and adverse effect of thalidomide regimen in treatment of invasive non-Hodgkin lymphoma(NHL).Methods Fifty-two patients with invasive NHL were divided into two groups randomly,with twenty-six patients in each group.In CHOP regimen(cyclophosphamide 600 mg/m~2 iv d1,epirubicin 50 mg/m~2 iv d1,vincristine 1.4 mg/m~2 iv d1,prednisone 50 mg/m~2 d1-d7)were given.In thalidomide regimen,the same shema with the CHOP regimen exception thalidomide,thalidomide 200 mg/m~2 po d1-d14 in the first course,400 mg/m~2 po d1-d14 in the second time of therapy were given.Results The response rate(RR)of CHOP regimen and thalidomide regimen were 73.1% and 88.4 %,respectively.There was no significant difference(P＞0.05).the OS rate in the first year and the second year of CHOP regimen and thalidomide regimen were 90.8 % and 68.8 %,92.6 % and 83.5 %,respectively,There was no significant difference in the first year of OS(P ＞0.05).There was significant difference in the second year of OS(P ＜0.05).The major side effect of the Two groups had significant difference(P ＜0.05).Conclusion Thalidomide combined with CHOP regimen on treatment of invasive NHL showed better efficacy than CHOP regimen on invasive NHL.The toxic reactions are tolerable.
